Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung cancer: experimental drug SSGJ-706 enters phase 2 trial

NCT ID NCT07171606

Recruiting now Disease control Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 24 times

Summary

This study tests a new drug called SSGJ-706, alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has not been treated before. About 240 adults will take part to see if the drug shrinks tumors and to check for side effects. The goal is to control the disease, not cure it, as ongoing management is expected.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIRST-LINE ADVANCED NSCLC PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Institute of The Shanghai Pulmonary Hospital

    RECRUITING

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

FIRST-LINE ADVANCED NSCLC PATIENTS